Sanofi said Japan’s Ministry of Health, Labour and Welfare has approved Sarclisa (isatuximab) in a subcutaneous formulation for use in multiple myeloma, extending the option for patients beyond intravenous dosing. The decision covers several combination regimens for both newly diagnosed and relapsed or refractory patients, with the approval grounded in clinical evidence showing non-inferiority to the intravenous version.
Shares in Paris were up after the announcement, indicating investor interest in Sanofi’s efforts to broaden convenience-focused oncology delivery and potentially improve uptake of its multiple myeloma franchise in a key market.
Key takeaways
- Price move: Sanofi shares in Paris were trading higher at the time of the update, up 1.92%.
- Catalyst: Japan approved the subcutaneous (SC) Sarclisa formulation for multiple myeloma in combination with standard-of-care regimens.
- Clinical basis: The approval relied on results from the IRAKLIA phase 3 study, which reported non-inferiority of the SC formulation versus intravenous dosing.
- Implication for treatment delivery: Sanofi is also pursuing approval of an on-body injector version, which—if cleared—could further reduce treatment burden.
What drove the move
Sanofi said Japan granted approval for Sarclisa’s SC formulation when used alongside approved standard therapies for multiple myeloma. The indicated combinations include:
- Relapsed or refractory multiple myeloma: Sarclisa SC in combination with pomalidomide and dexamethasone, or with carfilzomib.
- Newly diagnosed multiple myeloma: Sarclisa SC in combination with bortezomib, lenalidomide, and dexamethasone for adult patients.
Sanofi attributed the regulatory decision to data from the IRAKLIA phase 3 study in relapsed or refractory multiple myeloma, where the company said the SC formulation was non-inferior to the intravenous version. It also cited “supportive studies” supporting the overall application.
Market reaction and what investors are likely watching
The approval arrives as investors track whether more convenient formulations can accelerate penetration and improve patient adherence in chronic, long-duration oncology treatments. While the announcement did not provide new commercial targets or financial guidance, the addition of SC dosing can be meaningful for administration workflows, particularly for patients and healthcare settings that have relied on clinic-based intravenous infusions.
In practical terms, an SC option can reduce time spent on infusion visits compared with intravenous delivery, potentially supporting demand as clinicians consider administration preferences and treatment logistics. The market also appears to be monitoring the next step in Sanofi’s delivery strategy—an on-body injector format that may offer an even lower-friction administration method.
Next step: potential on-body injector in Japan
Sanofi also noted that a regulatory submission for the CirCLIQ on-body injector (OBI), based on the enFuse platform and submitted by Enable Injections, is under review in Japan. If approved, Sanofi said Sarclisa SC could become the first anticancer treatment administered via an on-body injector in Japan.
The company added that it would also represent the first multiple myeloma medicine in Japan to offer both a manual SC injection and OBI administration.
Sanofi’s delivery strategy is already progressing in other regions. The company said Sarclisa SC administered through both the CirCLIQ OBI and manual injection was approved in the European Union for multiple myeloma indications and combinations currently supported by the intravenous formulation, with the EU approval dated to June 2026. In the United States, Sanofi said an application for Sarclisa SC via both OBI and manual injection is under review.
Bigger picture for Sanofi’s oncology push
In Japan, Sarclisa’s intravenous formulation is already approved across five indications, including combinations using VRd (bortezomib, lenalidomide, and dexamethasone) in newly diagnosed multiple myeloma, plus four different regimen options in relapsed or refractory multiple myeloma.
With the new approval of the subcutaneous formulation, Sanofi is effectively adding a parallel administration pathway for key treatment settings. Investors typically view such label expansions—especially when they target convenience and ease of administration—as incremental steps that can support broader adoption, reduce treatment friction, and improve patient experience, though near-term financial impact was not specified in the announcement.
Olivier Nataf, Global Head of Oncology at Sanofi, said the new formulation “significantly eases treatment burden and enhances convenience for patients compared to intravenous administration,” and described it as having the potential to become Japan’s first anticancer therapy delivered via an on-body injector.
What to watch next: Sanofi will likely be focused on the outcome of the CirCLIQ on-body injector review in Japan, including any timelines and label details that could affect rollout. Investors may also look for updates on ongoing submissions in the United States, alongside broader multiple myeloma competitive dynamics and any further regulatory actions that expand Sarclisa’s administration options.
